Intratumorally implanted mesenchymal stromal cells potentiate peripheral immunotherapy against malignant rat gliomas.
Ströjby, Salina ; Eberstål, Sofia LU ; Svensson, Andreas LU ; Fritzell, Sara LU ; Bexell, Daniel LU ; Siesjö, Peter LU
; Darabi, Anna
LU
and Bengzon, Johan
LU
(2014)
In Journal of Neuroimmunology
274(1-2).
p.240-243
- Abstract
- Bone marrow-derived mesenchymal stromal cells (MSCs) target glioma extensions and micro-satellites efficiently when implanted intratumorally. Here, we report that intratumoral implantation of MSCs and peripheral immunotherapy with interferon-gamma (IFNγ) producing tumor cells improve the survival of glioma-bearing rats (54% cure rate) compared to MSC alone (0% cure rate) or immunotherapy alone (21% cure rate) by enforcing an intratumoral CD8(+) T cell response. Further analysis revealed that the MSCs up-regulate MHC classes I and II in response to IFNγ treatment in vitro and secrete low amounts of immunosuppressive molecules prostaglandin E2 and interleukin-10.
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4615653
- author
- Ströjby, Salina
; Eberstål, Sofia
LU
; Svensson, Andreas
LU
; Fritzell, Sara
LU
; Bexell, Daniel
LU
; Siesjö, Peter
LU
; Darabi, Anna
LU
and Bengzon, Johan
LU
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Journal of Neuroimmunology
- volume
- 274
- issue
- 1-2
- pages
- 240 - 243
- publisher
- Elsevier
- external identifiers
-
- pmid:25086876
- wos:000342871600033
- scopus:84906937667
- pmid:25086876
- ISSN
- 1872-8421
- DOI
- 10.1016/j.jneuroim.2014.07.014
- language
- English
- LU publication?
- yes
- id
- e3e89d2d-6837-44b2-8299-75221547b09a (old id 4615653)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/25086876?dopt=Abstract
- date added to LUP
- 2016-04-01 10:15:13
- date last changed
- 2022-02-17 08:16:13
@article{e3e89d2d-6837-44b2-8299-75221547b09a,
abstract = {{Bone marrow-derived mesenchymal stromal cells (MSCs) target glioma extensions and micro-satellites efficiently when implanted intratumorally. Here, we report that intratumoral implantation of MSCs and peripheral immunotherapy with interferon-gamma (IFNγ) producing tumor cells improve the survival of glioma-bearing rats (54% cure rate) compared to MSC alone (0% cure rate) or immunotherapy alone (21% cure rate) by enforcing an intratumoral CD8(+) T cell response. Further analysis revealed that the MSCs up-regulate MHC classes I and II in response to IFNγ treatment in vitro and secrete low amounts of immunosuppressive molecules prostaglandin E2 and interleukin-10.}},
author = {{Ströjby, Salina and Eberstål, Sofia and Svensson, Andreas and Fritzell, Sara and Bexell, Daniel and Siesjö, Peter and Darabi, Anna and Bengzon, Johan}},
issn = {{1872-8421}},
language = {{eng}},
number = {{1-2}},
pages = {{240--243}},
publisher = {{Elsevier}},
series = {{Journal of Neuroimmunology}},
title = {{Intratumorally implanted mesenchymal stromal cells potentiate peripheral immunotherapy against malignant rat gliomas.}},
url = {{http://dx.doi.org/10.1016/j.jneuroim.2014.07.014}},
doi = {{10.1016/j.jneuroim.2014.07.014}},
volume = {{274}},
year = {{2014}},
}